Key result
Anti-Xa activity does not differ significantly between elderly and nonelderly AF patients taking xabans.
Why the study?
What is the anti-Xa activity in elderly patients with atrial fibrillation treated with Factor Xa inhibitors?
Observational (n=58)
What is the anti-Xa activity in elderly patients with atrial fibrillation treated with Factor Xa inhibitors?
Answers are grounded in this paper and cite their sources.
Variable anti-Xa activity in elderly AF patients on xabans warrants caution; leaves open whether monitoring improves outcomes.
To the Editor: There are limited data about non–vitamin K oral anticoagulants on-treatment levels/activity in elderly patients with atrial fibrillation (AF). In fact, this activity probably correlates with the risk of adverse events1–3, and therefore, knowing the on-treatment activity might be off clinical importance especially in elderly individuals requiring long-term non–vitamin K oral anticoagulant therapy. We have previously showed that elderly might affect dabigatran ontreatment levels in AF patients.4 As there are no postmarketing data regarding the on-treatment anti-Xa activity (AXaA) in elderly patients receiving xabans, the aim of our study was to assess the trough and peak AXaA in elderly rivaroxabanand apixaban-treated patients with AF. Thus, a pilot, prospective, observational, postmarketing study in AF patients on xabans (rivaroxaban or apixaban) was performed. We enrolled 58 consecutive patients (22 men, 36 women) with AF: 18 elderly ($75 years; mean age 84.0, age range 78–92 years) rivaroxaban-treated (15 mg daily), 16 nonelderly (#70 years; mean age 60.5, age range 35–68 years) rivaroxaban-treated (20 mg daily), 14 elderly ($75 years; mean age 82.2, age range 78–86 years) apixaban-treated (2.5 mg twice daily), and 10 nonelderly (#70 years; mean age 64.8, age range 54–69 years) apixaban-treated (5 mg twice daily) patients. The exclusion criteria and statistical analysis were the same as in our previously mentioned analysis.4 The average duration of xabans therapy before performing the AXaA assessment was 58.5 days. The compliance was verified by a medical professional. Rivaroxaban was administrated at 7:00 AM; apixaban was administrated at 7:00 PM and 7:00 AM No other antiplatelet/ anticoagulant agents were administrated in studied population. The decision on concomitant medication was left to the attending physician. Blood samples were taken for the assessment of drug trough (at 7:00 AM) and peak (at 9:00 AM in rivaroxabantreated and 10:00 AM in apixaban-treated patients) AXaA. All patients were tested on the 5th day of their in-hospital stay (patients took 113 doses of rivaroxaban and 234 doses of apixaban prior blood sampling) and had eaten standard breakfast before the drug administration. All samples were analyzed within an hour after sampling with factor Xa-calibrated anti-Xa chromogenic analysis.5 The results of AXaA were expressed in ng/mL. There were no significant differences in the length of rivaroxaban and apixaban therapy between elderly and nonelderly individuals. The duration of therapy, basic demographics, and medication in xabans-treated patients are reported in Supplemental Digital Contents 1 and 2 (see Supplementary Materials 1 and 2, http://links.lww.com/AJT/A62 and http://links. lww.com/AJT/A63, respectively). Comparing elderly and nonelderly rivaroxaban-treated patients, there were no significant differences in trough (39.9 6 30.8 vs. 54.1 6 36.6 ng/mL, P5 0.28) and peak (190.9 6 89. 4 vs. 185.7 6 118.3 ng/mL, P 5 0.79) AXaA (Table 1). Similarly, the trough AXaA (Table 1) did not differ significantly in apixaban-treated elderly patients when compared with apixaban-treated nonelderly individuals (111.3 6 69.6 vs. 70.5 6 41.5 ng/mL, P 5 0.09). Furthermore, no significant differences were found in apixaban peak AXaA (Table 1) between elderly and nonelderly apixaban-treated patients with AF (187.4 6 81.6 vs. 158.3 6 91.6 ng/mL, P 5 0.43). As elderly patients have higher risk of adverse events in the settings of AF, knowing the on-treatment AXaA might be off clinical importance especially in these patients. The AXaA on xabans was previously studied in younger individuals6 or in patients taking preventive doses during orthopedic surgery7; however, the data mapping this activity in elderly AF patients are still very poor. Considering the fact that dabigatran4 and edoxaban8 levels might be American Journal of Therapeutics 27, e507–561 (2020)
No takes yet. Share an insight, caveat, or question.
Samoš et al. (2019) conducted an observational in Atrial fibrillation (n=58). Xabans (rivaroxaban or apixaban) in elderly patients vs. Xabans in nonelderly patients (≤70 years) was evaluated on Trough and peak anti-Xa activity (AXaA). Trough and peak anti-Xa activity did not differ significantly between elderly (≥75 years) and nonelderly (≤70 years) patients with atrial fibrillation treated with rivaroxaban or apixaban.
Synapse has enriched 10 related papers. Consider them for comparative context: